SCHEMBL2908192

SCHEMBL2908192

COc1cc(NC(c2ccc(C(=O)OC(C)(C)C)cc2)c2cncs2)ccc1C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IMPDH2 P12268 1/20 0.36
IMPDH1 P20839 1/20 0.36
PIM3 Q86V86 1/20 0.34
AAK1 Q2M2I8 1/20 0.33
STAT3 P40763 2/20 0.32
ABCG2 Q9UNQ0 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PPARG P37231 1/20 0.32
PPARA Q07869 1/20 0.32
NR1H4 Q96RI1 1/20 0.32
RORC P51449 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
PIM1 P11309 1/20 0.31
CSNK2A1 P68400 1/20 0.31
MEN1 O00255 2/20 0.31
MAPT P10636 2/20 0.31
KMT2A Q03164 2/20 0.31
CD38 P28907 1/20 0.31
P2RX7 Q99572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905041 0.87 CD38 (0.36) IMPDH2IMPDH1AAK1STAT3MEN1
SCHEMBL2908019 0.83 KCNQ3 (0.37) IMPDH2IMPDH1LMNARAB9AAURKA
SCHEMBL2908813 0.81 MKNK1 (0.35) ABCG2ALDH1A1KMT2ARAB9AHTR1A
SCHEMBL3129124 0.81 SMN1; SMN2 (0.37) IMPDH2IMPDH1ALDH1A1MEN1MAPT
SCHEMBL2907448 0.77 TMPRSS15 (0.36) ABCG2MEN1MAPTKMT2ALMNA
SCHEMBL2908195 0.71 HDAC6 (0.34) ALDH1A1PPARGPPARAMEN1MAPT
SCHEMBL7401464 0.71 ALDH1A1 (0.53) ALDH1A1PPARGPPARAPIM1MAPT
SCHEMBL7403879 0.66 ALDH1A1 (0.55) IMPDH2IMPDH1ALDH1A1NR1H4MEN1
SCHEMBL2910933 0.66 PDE4D (0.40) ABCG2ALDH1A1MEN1MAPTKMT2A
SCHEMBL2901840 0.66 ALDH1A1 (0.35) IMPDH2IMPDH1ALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
EP-1692109-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS Memory Pharmaceuticals Corporation (US) 2006-08-23 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B IMPDH2 304/4885IMPDH1 153/4885PIM3 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.